A good candidate for Semaglutide GLP-1 weight loss treatment is typically an adult with a body mass index (BMI) of 30 or higher, which classifies them as obese, or an individual with a BMI of 27 or higher who also has weight-related health conditions such as type 2 diabetes, high blood pressure, or sleep apnea
With options for both oral and injectable treatments, and a team to support you, Klinic ensures a smooth experience
The same caveat applies: the injectable format has robust clinical trial backing while the oral compounded version does not
GHRP-6 produces the most intense appetite stimulation of any synthetic GHRP, substantially more than GHRP-2 and far more than ipamorelin, which produces negligible hunger at standard doses
Evaluate whether your dose needs adjustment
Zepbound: Tirzepatide Administered weekly, Zepbound targets both GLP-1 and GIP receptors and holds the record for the highest weight loss efficacy, achieving up to 20.9% weight reduction in clinical studies